All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, February 1, 2023
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Other news to note for Feb. 4, 2020

Feb. 4, 2020
No Comments
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Advaccine, Anticancer, Asahi Kasei, Aspen, Avacta, BGI, Biolexis, Celularity, Clover, Curetis, Curevac, Daewoong, Duke-National University, Horizon, Inovio, Novartis, Outlook, Oxford Gene Technology, Sandoz, Sorrento, Sysmex, Takeda, Veloxis, Wuhan Institute of Virology, Wuxi Biologics.
Read More

Regulatory front for Feb. 4, 2020

Feb. 4, 2020
No Comments
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: GE Healthcare.
Read More

Other news to note for Feb. 4, 2020

Feb. 4, 2020
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aevi Genomics, Anika, Anteros, Athenex, Arthrosurface, Beijing CC-Pharming, Biomotiv, Biosense Webster, BMS, Boehringer, Cerecor, Contrafect, Cormedix, CNS Pharmaceuticals, Equinox, Eyepoint, FSD, Genekam, Ibio, Inprother, Levena, Mablytics, Navrogen, Pattern Bioscience, Plex, Porton Pharma, Q Biomed, Rhythm AI, Salarius, Samus, Sirion, Solarvest, Syntrix, Theratechnologies, Trefoil, Trianni.
Read More
2-3-Azar-HHS.png

HHS declares public health emergency in part because CDC test for coronavirus unreliable

Feb. 3, 2020
By Mark McCarty
No Comments
The U.S. Department of Health and Human Services has declared a public health emergency in the U.S. over the coronavirus in part because a government diagnostic for the virus yields inconsistent results, a fact that may spur the life sciences to provide a solution.
Read More
2-3-Novacyt-primerdesign-genesig-16.png

Novacyt launches test for new coronavirus

Feb. 3, 2020
By Meg Bryant
No Comments
As the deadly coronavirus continues to spread, countries around the world are scrambling to understand the public health threat and identify and quarantine people who may be infected. To that end, Novacyt SA has launched a molecular test that detects only the 2019 strain of the coronavirus, reducing the chance of false diagnoses.
Read More
Man wearing mask, receiving coronavirus vaccine

Gilead’s remdesivir enters China phase III trial to fight coronavirus

Feb. 3, 2020
By Elise Mak
No Comments
BEIJING – China will kickstart a phase III trial Feb. 3 to determine whether patients with 2019-nCoV can be treated with Gilead Sciences Inc.’s NUC inhibitor, remdesivir, which was originally developed for Ebola, four days after a U.S. patient was said to have recovered by using the drug candidate. 
Read More

Other news to note for Feb. 3, 2020

Feb. 3, 2020
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Agex, Anticancer, Applied Biomath, Artelo, Aspen Global, Astrazeneca, Avacta, Be Cool, Biomx, Cellink, Citius, Daewoong, Enochian, Gritstone, Inovio, Nektar, Novartis, Precigen, PTC Therapeutics, Sandoz.
Read More
DNA

Bench Press for Jan. 31, 2020

Jan. 31, 2020
By Anette Breindl
No Comments
BioWorld looks at translational medicine, including: Adapting NGS for coronavirus surveillance; Long QT genes mostly short on evidence; Reservoir dogs don’t hunt; Another reason to get a flu shot; Cerebrospinal fluid is early culprit in stroke edema; Different drivers can turn the wheel in glioblastoma’s vicious cycle; From African genomes, big insights with small sample size; Commercial antibodies underwhelm for studies of PP2A; Tau keeps gliomas in check.
Read More
Time perception clocks

With rapid transmission of 2019-nCoV, how fast is fast enough for communication?

Jan. 31, 2020
By Anette Breindl and Elise Mak
No Comments
BEIJING – The current speed of new developments in the 2019-nCov outbreak is illustrated by a Jan. 28, 2020, press conference in Munich, where Andreas Zapf, head of the infection task force in the Bavarian ministry for health and food safety, briefed reporters on the first confirmed German case.
Read More

Other news to note for Jan. 31, 2020

Jan. 31, 2020
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aspen, Curevac, Follicum, Fuzionaire, ICER, Nanoviricides, Novartis, Predictive Oncology, Quantitative Medicine, Saromics, Vaxart, Ziopharm.
Read More
Previous 1 2 … 474 475 476 477 478 479 480 481 482 … 495 496 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan. 31, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 31, 2022.
  • Setpoint Medical - vagus nerve stimulation device

    Setpoint Medical lands up to $145M to advance RA implant

    BioWorld MedTech
    Bioelectronic medicine startup Setpoint Medical Corp. raised $80 million in a preferred stock financing co-led by new investors Norwest Venture Partners and...
  • Stem-cells2.png

    J.P. Morgan Healthcare Conference: ‘Bright’ year ahead for cell, gene therapies, says ARM

    BioWorld
    After long years of painstaking work, the commercialization of cell and gene therapies picked up pace in 2022, with multiple approvals. More progress is expected...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing